ReviewFrontiers in aging2023
Recent clinical trials with stem cells to slow or reverse normal aging processes.
Review in Frontiers in aging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Efficacy of Treadmill Training on Balance and Fall Risks in the Elderly: A Systematic Review."F1000Research · 2024Pooled it
- Metabolomics-guided isolation of myogenic progenitor cells for improved transplantation.American journal of physiology. Cell physiology · 2026Article
- Serum-induced recovery of proliferative capacity and differentiation potential in aged dental pulp stem cells.Stem cells translational medicine · 2026Article
- Review
- Stem Cells in Aging and Anti-Aging.Stem cell reviews and reports · 2026Review
- Sarcopenia and Muscle Aging: Updated Insights into Molecular Mechanisms and Translational Therapeutics.Endocrinology and metabolism (Seoul, Korea) · 2026Review
- Periodic Therapeutic Phlebotomy Mitigates Systemic Aging Phenotypes by Promoting Bone Marrow Function.Aging cell · 2026Article
- Intradermal Application of Allogenic Wharton's Jelly Mesenchymal Stem Cells for Chronic Post-Thoracotomy Wound in an Elderly Patient After Coronary Artery Bypass Grafting: Clinical Case with Brief Literature Review.Diseases (Basel, Switzerland) · 2026Article
- Stem cell dysfunction and rejuvenation strategies in ageing: emerging advances in regenerative medicine.Frontiers in cell and developmental biology · 2026Review
- Clinically Meaningful or Just Measurable? What Physiologic Outcomes Tell Us About Aging Interventions.Current geriatrics reports · 2025Article
- JIB-04 improves PPARγ expression and enhances adipogenic differentiation efficiency in human umbilical cord mesenchymal stem cells.Biochemistry and biophysics reports · 2025Article
- Age-related changes in the proteome and mitochondrial metabolism of rabbit adipose-derived stromal/stem cells.Scientific reports · 2025Article
- Targeting cellular senescence in kidney diseases and aging: A focus on mesenchymal stem cells and their paracrine factors.Cell communication and signaling : CCS · 2024Review
- From Bench to Bedside: Translating Cellular Rejuvenation Therapies into Clinical Applications.Cells · 2024Review
- qMAP enabled microanatomical mapping of human skin aging.bioRxiv : the preprint server for biology · 2024Article
- Review
- Climbing the longevity pyramid: overview of evidence-driven healthcare prevention strategies for human longevity.Frontiers in aging · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aging is associated with a decline in the regenerative potential of stem cells. In recent years, several clinical trials have been launched in order to evaluate the efficacy of mesenchymal stem cell interventions to slow or reverse normal aging processes (aging conditions). Information concerning those clinical trials was extracted from national and international databases (United States, EU, China, Japan, and World Health Organization). Mesenchymal stem cell preparations were in development for two main aging conditions: physical frailty and facial skin aging. With regard to physical frailty, positive results have been obtained in phase II studies with intravenous Lomecel-B (an allogeneic bone marrow stem cell preparation), and a phase I/II study with an allogeneic preparation of umbilical cord-derived stem cells was recently completed. With regard to facial skin aging, positive results have been obtained with an autologous preparation of adipose-derived stem cells. A further sixteen clinical trials for physical frailty and facial skin aging are currently underway. Reducing physical frailty with intravenous mesenchymal stem cell administration can increase healthy life expectancy and decrease costs to the public health system. However, intravenous administration runs the risk of entrapment of the stem cells in the lungs (and could raise safety concerns). In addition to aesthetic purposes, clinical research on facial skin aging allows direct evaluation of tissue regeneration using sophisticated and precise methods. Therefore, research on both conditions is complementary, which facilitates a global vision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.